1.Eriksen C. U., Rotar O., Toft U., Jorgensen T. What is the effectiveness of systematic population –level screening programmes for reducing the burden of cardiovascular diseases? –Copenhagen: WHO Regional Office for Europe. –2021. –107 p.2.Шляхто Е. В., Звартау Н. Э., Виллевальде С. В., соавт. Система управления сердечно­сосудистыми рисками: предпосылки ксозданию, принципы организации, таргетные группы // Российский кардиологический журнал. − 2019. − No11. −С. 69­82, doi.org/10.15829/1560-4071-2019-11-69-82.3.Than N. N., Newsome P. N. A concise review of non-alcoholic fatty liver disease // Atherosclerosis. –2015. –V.239. –P. 192-2024.Arslan U, Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease // World J Clin Cases. –2020. -8(20). –P. 4688-4699.5.Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020 Apr;51(7):728-736. doi: 10.1111/apt.15660.6.Trovato F. M., Martines G. F., Catalano D., et al. Echocardiography and NAFLD (non-alcoholic fatty liver disease) // Int J Cardiol. –2016. –No221. –Р. 275–284.7.Fracanzani A. L., Pisano G., Consonni D., etal. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease // PLoS ONE. –2016. –Vol. 11 (9). –Р. 16-24, doi:10.1371/journal.pone.0162473.8.Stahl E. P., Dhindsa D. S., Lee S. K., et al. Non-alcoholic Fatty Liver Disease andtheHeart // Journal of the American College of Cardiology. –2019. –No73 (8). –Р. 948-963, doi:10.1016/j.jacc.2018.11.050.